EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma.

导出 OA

翻译打印收藏纠错

作者： Kyriaki,Tzogani ^[1] ; Paula,van Hennik ^[2] ; Ita,Walsh ^[3] ; Pieter,De Graeff ^[2] ; Annika,Folin ^[3] ; Jan,Sjöberg ^[2] ; Tomas,Salmonson ^[3] ; Jonas,Bergh ^[2] ; Edward,Laane ^[4] ; Heinz,Ludwig ^[2] ; Christian,Gisselbrecht ^[4] ; Francesco,Pignatti ^[2]

作者单位： European Medicines Agency, London, United Kingdom kyriaki.tzogani@ema.europa.eu. ^[1] European Medicines Agency, London, United Kingdom. ^[2] Medicines Evaluation Board, Den Haag, The Netherlands. ^[3] Läkemedelsverket, Medicinal Products Agency, Uppsala, Sweden. ^[4] Karolinska Institutet and University Hospital, Radumhemmet, Karolinska Oncology, Stockholm, Sweden. ^[5] North Estonia Regional Hospital, Tallinn, Estonia. ^[6] Wilhelminen Cancer Research Institute, Vienna, Austria. ^[7] Hospital Saint Louis, Paris, France. ^[8]

关键词 European Medicines Agency Multiple myeloma Panobinostat

主题词抗肿瘤药(Antineoplastic Agents);女(雌)性(Female);人类(Humans);男(雄)性(Male);多发性骨髓瘤(Multiple Myeloma);肿瘤复发, 局部(Neoplasm Recurrence, Local)

DOI 10.1634/theoncologist.2017-0301

PMID 29192015

发布时间 2019-09-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交